Please check your internet connection and try again.
# Meftal spas
## Overview
Meftal spas is a combination product containing mefenamic acid and dicyclomine hydrochloride. Mefenamic acid is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis. Dicyclomine hydrochloride is an anticholinergic and antispasmodic agent that reduces gastrointestinal motility and secretions.
## Primary Indications
* Symptomatic treatment of moderate to severe pain associated with:
* Abdominal cramps
* Gastrointestinal spasms
* Dysmenorrhea
## Adult Dosing
* **Meftal spas tablet:** 1 tablet (mefenamic acid 250 mg, dicyclomine HCl 20 mg) three times daily.
* **Maximum dose:** Generally, not to exceed 6 tablets per day. Specific maximum daily doses should be guided by local protocols and patient response.
## Pediatric Dosing
* Information regarding the safety and efficacy of Meftal spas in pediatric patients is limited. Use in children is generally not recommended unless specifically indicated and dosed under expert medical guidance. If used, dosing would likely be based on weight and age, with careful monitoring for adverse effects.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Mefenamic acid is primarily renally excreted. Dose reduction may be necessary in severe renal impairment.
* **Hepatic Impairment:** Use with caution. Mefenamic acid can affect liver function.
* **Elderly:** Use with caution, as they are more susceptible to adverse effects, particularly gastrointestinal bleeding and renal dysfunction.
## Contraindications
* Hypersensitivity to mefenamic acid, dicyclomine, or any component of the formulation.
* Patients with a history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs.
* Inflammatory bowel disease.
* Gastrointestinal obstruction, paralytic ileus, or severe ulcerative colitis.
* Glaucoma.
* Myasthenia gravis.
* Severe renal or hepatic impairment.
* Third trimester of pregnancy.
* Known or suspected pyloric or duodenal obstruction, achalasia, or cardiospasm.
## Adverse Effects
* **Common:** Nausea, vomiting, diarrhea, abdominal pain, constipation, dizziness, blurred vision, dry mouth.
* **Serious:**
* **Gastrointestinal:** GI bleeding, ulceration, perforation.
* **Cardiovascular:** Increased risk of myocardial infarction, stroke.
* **Renal:** Renal papillary necrosis, interstitial nephritis, renal failure.
* **Hepatic:** Hepatitis, jaundice.
* **Dermatologic:** Stevens-Johnson syndrome, toxic epidermal necrolysis.
* **Hematologic:** Anemia, leukopenia, thrombocytopenia.
* **Anticholinergic effects:** Urinary retention, constipation, dilated pupils, blurred vision, tachycardia, confusion.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin):** Increased risk of bleeding.
* **Other NSAIDs and Aspirin:** Increased risk of GI toxicity and bleeding.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **ACE inhibitors and Angiotensin II Receptor Blockers:** May reduce antihypertensive effect and increase risk of renal impairment.
* **Diuretics:** May reduce diuretic efficacy and increase risk of renal toxicity.
* **Lithium:** NSAIDs can increase serum lithium levels.
* **Methotrexate:** NSAIDs can increase methotrexate toxicity.
* **Anticholinergics (e.g., tricyclic antidepressants, antihistamines):** Additive anticholinergic effects.
* **MAO inhibitors:** May potentiate anticholinergic effects.
## Monitoring
* **Renal function:** Baseline and periodic monitoring, especially in patients with pre-existing renal disease or those at risk.
* **Hepatic function:** Baseline and periodic monitoring, especially in patients with liver disease.
* **Signs of GI bleeding:** Monitor for melena, hematemesis, or occult blood in stool.
* **Blood pressure:** Especially with concomitant antihypertensive therapy.
* **Signs of anticholinergic effects:** Monitor for dry mouth, blurred vision, urinary retention, constipation.
## Clinical Pearls
* Meftal spas should be used at the lowest effective dose for the shortest duration necessary to control symptoms.
* Consider gastroprotection (e.g., proton pump inhibitor) for patients at high risk of GI complications.
* Avoid concomitant use with other NSAIDs.
* Educate patients on the signs and symptoms of GI bleeding and to seek medical attention immediately if they occur.
* Caution patients about potential drowsiness and impairment of mental and physical abilities.
***
*Disclaimer: This information is intended for healthcare professionals. Always consult the most current prescribing information and relevant guidelines before making clinical decisions. This information does not replace professional medical advice.*
